Elan starts to produce MS drug

ELAN has started production of Antegren, its multiple sclerosis (MS) drug, in advance of a possible launch in 2005.

Elan gave a detailed briefing to stockbroking analysts on Monday. They were told the company anticipates approval for Antegren from the US Food and Drug Administration to permit sales to start by early 2005.

Merrion's Peter Frawley said, in a note to clients, Elan's greatest concern is not the approval process but rather managing the demand and supply curve.